Full TitlePhase 2 trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have recurrent or metastatic squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of the NSD3 gene.
- At least 2 weeks must pass since the completion of previous treatment and receipt of ZEN003694.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information about this study and to ask about eligibility, please contact the office of Dr. Paul Paik at 646-608-3759.